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Abstract
Background: X-linked Adrenal Hypoplasia Congenita (AHC) is a rare cause of primary adrenal insufficiency due to
mutations in the NR0B1 gene, causing a loss of function of the nuclear receptor protein DAX-1. Adrenal insufficiency
usually appears in the first 2 months of life, but can sometimes emerge during childhood. Hypogonadotropic
Hypogonadism is often associated later in life and patients may develop azoospermia. We describe an unusual
onset of AHC started with isolated hypoaldosteronism as first and only sign of the disease.
Case presentation: A 18-days-old newborn presented with failure to thrive and feeding difficulties. Blood tests
showed severe hyponatremia, hyperkalemia and hypochloremia. Renin was found over the measurable range and
aldosterone was low whereas cortisol level was normal with a slightly increased ACTH. In the suspicion of Primary
Hypoaldosteronism, correction of plasmatic electrolytes and replacement therapy with Fludrocortisone were
promptly started. The subsequent evidence of low plasmatic and urinary cortisol and increased ACTH required the
start of Hydrocortisone replacement therapy and it defined a clinical picture of adrenal insufficiency. Genetic
analysis demonstrated a novel mutation in the DAX-1 gene leading to the diagnosis of AHC.
Conclusions: AHC onset may involve the aldosterone production itself, miming an isolated defect of aldosterone
synthesis. NR0B1/DAX-1 mutations should be considered in male infants presenting with isolated hypoaldosteronism
as first sign of adrenal insufficiency.
Keywords: NR0B1, DAX-1, X-linked adrenal hypoplasia congenita, Adrenal insufficiency, Hypoaldosteronism,
Mineralocorticoid deficiency
Background
X-linked Adrenal Hypoplasia Congenita (AHC; OMIM
#300200) is a congenital disorder characterized by adrenal
insufficiency, often associated with hypogonadotropic hypo-
gonadism. The first case, described in 1948, was a male
who died at 33 days of life for adrenal crisis with salt wast-
ing [1]. The estimated incidence is 1 in 12,500 births. AHC
results from mutations in the NR0B1/DAX-1 gene, a nu-
clear receptor located on the X-chromosome (Xp21) and
expressed in adrenal cortex, gonads, hypothalamus and pi-
tuitary gland. DAX-1 regulates adrenal and reproductive
differentiation and function, although its role is not com-
pletely clear [2]. DAX-1 mutations are usually associated
with primary adrenal failure, hypogonadotropic hypogonad-
ism and impaired spermatogenesis (oligospermia or azoo-
spermia are typically present) although uncommon
phenotypes, different clinical features and different age of
onset have been described [2, 3]. More than 100 pathogenic
mutations of DAX-1 are known, together with deletions of
the exons or of the entire gene, most of which are located
at the carboxyl-terminal of the protein and are nonsense or
frameshift missense mutations. We present a newborn with
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isolated hypoaldosteronism as first sign of AHC caused by
a novel mutation (c.848_849delinsCC) of DAX-1 gene [4].
Case presentation
The male 18-days-old Caucasian newborn was admitted
to our department for ineffective breastfeeding and failure
to thrive. He was born at term from spontaneous delivery,
small for gestational age to non-consanguineous parents
[5]. Pregnancy was uneventful except for a delayed intra-
uterine growth restriction detected during the last month
of gestation. External genitalia were of normal appearance,
prepubertal, with testicular volumes of 1ml. Blood tests
showed a severe hyponatremia (Na + 110mEq/l; NR 136–
146mEq/l), hyperkalemia (K+ 7.5mEq/l; NR 3.5–5.30
mEq/l), hypochloremia (Cl- 81mEq/l; NR 97–110mEq/l)
and metabolic acidosis with increased lactate. Glycemia
was within the normal range for age (68mg/dl); urinary
sodium loss was also detected (Natriuria 16mEq/l).
Endocrinological tests revealed low plasmatic aldoster-
one levels (38.6 pg/ml; NR 50–300 pg/ml), dramatic in-
creased renin (44,100 μU/ml; NR 4.4–46.1), elevated
levels of adrenocorticotropic hormone (ACTH, 91.4 pg/
ml NR 4,3–52) and normal plasmatic cortisol (13.7 μg/dl
Table 1 Medical history timeline where auxological parameters during the first 2 years of life and biochemical and hormonal values
are summarized.
Chronologic
Age (years)
38 + 2
weeks
of GA
(Birth)
40 + 2
weeks of
GA
(hospital
admission)
0.3 0.47 0.6 0.8 1.2 1.77 2.1
Length (cm)
(°p)a
/ / 57.6 (1.6) 62.3 (1.5) 65.9 (5) 70 (10) 76 (16) 82.6 (17) 85.3 (18)
Weight (Kg)
(°p)a
2.505
(5)
2.450 (<<
3)
4.81 (< 3) 5.66 (< 3) 6.46 (< 3) 7.51 (3–10) 9.47 (47) 11 (57) 12.2 (53)
Head
Circumference
(cm)
/ / 39 41 42.5 44 46 47 48
Pubertal Stage
(testicular
volume)
/ P1,G1,A0
(1 ml
bilateral)
P1,G1,A0
(1 ml
bilateral)
P1,G1,A0
(1 ml
bilateral)
P1,G1,A0
(1 ml
bilateral)
P1,G1,A0
(1 ml
bilateral)
P1,G1,A0 (1 ml
bilateral)
P1,G1,A0 (2 ml
bilateral)
P1,G1,A0 (2 ml
bilateral)
ACTH (pg/ml) / 91.4 / 124.9 / 300 83.1 40.6 81.6
Cortisol / 13.7 / 4.4 5.2 7.4 19.4 13.2 19.5
Aldosterone
(pg/ml)
/ 38.6 / 55.9 45.2 21.5 16.7 16.4 15.2
Renin (μU/ml) / 44,100 / 181.2 / 123.6 5.6 2.5 23.4
17 OH
progesterone
(ng/ml)
/ 4.4 / / / 0.4 / 0.1 0.1
Na (mEq/L) / 110 138 134 139 139 140 138 139
K (mEq/L) / 7.5 5.7 4.9 5 4.2 4.8 4.5 4.3
DHEA-S (μg/
ml)
/ 1.09 / / / 0.03 / < 0.02 < 0.02
Testosterone
(ng/ml)
/ / / / / 0.2 / / < 0.1
Treatment / Fludro-
cortisone
50 mcg/
day
+ NaCl
11.6%
1ml × 7/
day
Fludro-
cortisone
100 mcg/
day
+
NaCl11.6%
1ml × 7/
day
Fludro-
cortisone
100 mcg/
day
+
NaCl11.6%
1ml × 7/
day
Fludro-
cortisone
100 mcg/
day
+
NaCl11.6%
1 ml × 7/
day
Started
Hydro-
cortisone
10 mg/m2/
day
+Fludro-
cortisone
100 mcg/
day
+
NaCl11.6%
1 ml × 7/
day
Hydro-cortisone
10 mg/m2/day +
Fludro-cortisone
100 mcg/day +
NaCl11.6% 1ml ×
7/day
Hydro-cortisone
10 mg/m2/day
+Fludro-cortisone
100 mcg/day +
NaCl11.6% 1ml ×
7/day
Hydro-cortisone
10mg/m2/day
+Fludro-cortisone
100 mcg/day +
NaCl11.6% 1ml ×
7/day
aPercentiles referred to the WHO growth charts for male infants (https://www.who.int/childgrowth/standards/en/)
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NR 6.7–22.6). Skin pigmentation was normal except for
mild pigmentation of the external genitalia. Neonatal
screening for 17-OH-progesterone was within the nor-
mal range. Electrolytes replacement first intravenous and
then oral, and therapy with Fludrocortisone (50 μg/die)
and salt integration were started with normalization of
clinical and hormonal conditions. Treatment revealed to
be effective and the newborn started growing properly,
with normal electrolytes. Cerebral ultrasounds and cere-
bral magnetic resonance (MRI) were normal, as well as
the elettrocardiogram (ECG) and chest X-rays. Abdom-
inal MRI showed normal size of the adrenal glands. A
diagnosis of Primary Hypoaldosteronism was entertained
and genetic analysis of the CYP11B2 gene (encoding
aldosynthase) was requested.
During the follow up after the first 5 months of life,
ACTH levels started increasing again although there was
a good treatment compliance, normal electrolytes, good
weight and length gain and slightly low basal cortisol
levels, within the normal range for age (Table 1).
At 9months of age the result of the CYP11B2 gene se-
quencing did not show any mutation. The parents refused
to accomplish a short synacthen test (SST), however basal
ACTH was 300 pg/ml and 24-h urine collection pointed
out low levels of urinary cortisol (20 μg/24 h, NR 58–
403 μg/24 h) with normal Na/K urinary ratio. Moreover,
normal serum 17-OH-progesterone was found, ruling out
the hypothesis of congenital adrenal hyperplasia (CAH).
Luteinizing hormone (LH) and follicle-stimulating hor-
mone (FSH) were found, respectively, of 1 IU/l and 2.2
IU/l, and Testosterone of 0.2 ng/ml, being to the highest
levels of the normal range for age.
A diagnosis of adrenal insufficiency was made and re-
placement therapy with Hydrocortisone (10 mg/m2/day),
joint to already in use Fludrocortisone therapy (100 μg/
day) and salt integration, was started. An abnormal de-
velopment of adrenal glands rather than an enzymatic
defect was hypothesized. Adrenal antibodies and very
long chain fatty acids (VLCFA) were negative. DNA ana-
lysis performed by Sanger sequencing identified a novel
Fig. 1 Partial chromatograms showing the novel NR0B1 /DAX-1 mutation. Base change c.848_849delinsCC leading to the missense mutation
p.(Gln283Pro). The reference sequence is in highlighted in red. The proband’s DNA sequence is above, the mother’s DNA sequence in the middle
and a healthy control’s sequence underneath
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in frame indel mutation in the NROB1 gene (c.848_
849delinsCC or p.(Gln283Pro)), confirming the diagnosis
of AHC. As expected the same mutation was carried by
the mother as hemizygous (see Fig. 1).
Discussion
We describe the case of a newborn presenting with un-
specific symptoms and silent family history, in which
AHC started with an isolated mineralocorticoid defi-
ciency, leading to the initial hypothesis of primary
hypoaldosteronism treated with fludrocortisone. The
negative results of CYP11B2 genetic analysis and the
tightened endocrinological follow-up allowed to discover
the secondary development of glucocorticoid deficiency,
although parents refused to perform a SST, and a
prompt supplementation therapy with hydrocortisone
was started before any adrenal crisis. The initial presen-
tation of pathogenic DAX-1 mutations is often a com-
bination of mineral and glucocorticoid deficiency but,
especially during the neonatal period, it is known how
aldosterone deficiency may precede cortisol deficiency at
onset, confounding the initial diagnosis. The reason of
this peculiar clinical appearance is still unknown, and re-
cent studies failed to establish a genotype phenotype
correlation in patients with NR0B1 mutations [6].
Generally, healthy newborns exhibit a renal tubular im-
maturity at birth, with sodium wasting and impaired water
reabsorption. Renal sodium reabsorption is mainly regu-
lated by aldosterone, through the binding of its receptor,
the mineralocorticoid receptor (MR), a transcription factor
regulating the expression of several transporting proteins
related to sodium homeostasis [7]. Soon after birth, chan-
ging from an intra-uterine aquatic environment to the out-
womb/terrestrial one, a partial aldosterone resistance is well
documented, with high plasma levels of aldosterone and
renin, contrasting with biological signs of functional
hypoaldosteronism (as hyponatremia, hyperkalemia and
urinary sodium loss). The highest aldosterone levels de-
tected in the cord blood at birth are consistent with the de
novo synthesis in the fetal adrenal gland, given the very
early expression of the aldosterone synthase gene starting
from 13 gestational weeks [8]. This hormonal resistance
could account for the weight loss observed during the first
days of life and might be an adaptive phenomenon of the
passage from the in utero to terrestrial life [9]. Neverthe-
less, the transient aldosterone resistance is associated with
low MR renal presence at birth, followed by a significant
increase in the postnatal period, with a complete renal
tubular expression developed during the first year of life,
contemporary to renal functional maturation [10]. It was
demonstrated that high aldosterone levels soon after birth
are required for the MR optimal up-regulation in the post-
natal period, and it is therefore indispensable for sodium
homeostasis [7]. Glucocorticoids are able to bind MR with
the same affinity of mineralocorticoids, being a possible
responsible for the development of MR during the first
year of life even in cases of hypoaldosteronism. Moreover,
basal cortisol levels at birth and during the first days/
months of life may be normal in patients with AHC, sign
of the possible adrenal transition from fetal to adult zone.
In fact, several adrenal enzymes responsible for steroids
synthesis of the fetus, are active since the very first weeks
of gestation, and may lead to the development of an “ad-
renal reserve”, during the neonatal and perinatal period,
responsible for the slow development of glucocorticoid
deficiency symptoms.
It is important to bear in mind that in boys, once
CAH has been ruled out, the most frequent cause of ad-
renal insufficiency in neonatal period are the DAX-1 mu-
tations. In our case, CAH was excluded by normal 17-
OH-progesterone levels at neonatal screening [11–13].
Afterwards, the DNA sequencing identified a novel in
frame indel mutation in the NR0B1 gene and the diag-
nosis of AHC was made. An indel was identified with
the deletion of two base-pair (bp) replaced by two cyto-
sine in position 848_849. The sequence variants is desig-
nated according to the Human Genome Society
recommendations (https://www.hgvs.org) using the Na-
tional Center for Biotechnology Information (NCBI) ref-
erence sequences NM_000475.4, NP_000466.2 built on
the GRCh37/hg19 and is NM_000475.4:c.848_
849delinsCC or p.(Gln283Pro).
Pathogenicity prediction was performed in silico using
several programs: Align-GVGD, Polyphen-2 and SIFT
and the variant was predicted to be most likely patho-
genic using Align-GVGD class, probably damaging,
using Polyphen-2, deleterious using SIFT. The Gran-
tham score that ranges from 0 to 215, was calculated to
predict the effect of substitutions between amino acids
based on chemical properties (i.e. polarity and molecular
volume). Higher scores indicate greater differences be-
tween two amino acids and may indicate a stronger
(negative) effect on protein structure and function. Phys-
icochemical effect of this variation is important with a
Grantham score of 76. Frequency databases (dbSNP,
ESP, and gnomAD) were searched to determine if the
variant had already been reported and it was not. It has
not been found in 100 Caucasian healthy controls se-
quences. According to the ACMG/AMP standards
Guidelines the variant is classified as pathogenic [14].
Since the first description of the NR0B1/DAX-1 muta-
tion in 1994 as the etiology of AHC, several novel muta-
tions have been discovered. Deletions, nonsense and
frameshift mutations of the carboxyl-terminal domain
seem to be the most common and are usually associated
to clinical phenotypes. Structure-function studies sug-
gest that mutations in the amino-terminal domain are
compensated by the presence of redundant LXXLL
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Table 2 Recent cases of ACH described in literature: main clinical and genetic characteristics
References Age at
presentation
Age at diagnosis Presentation Family history Genetic analysis
Evliyaoglu O, 2013 [11] 33 days ↓Na,↑K,
↓aldosterone,
↑renin, ↑ACTH,
↓cortisol
Both parents normal c.543delA
Abraham MB, 2016 [12] 5 years 5 years ↓Na,↑K,
↓aldosterone,
↑ACTH, ↓cortisol
Mother as a carrier c.844C > T
Wheeler B, 2008 [13] case 1 6 weeks 6 weeks ↓Na,↑K,
aldosterone N,
↑renin, ↑ACTH,
↓cortisol
Nucleotide
transversion
c.192C > A,
c.498G > A
Wheeler B, 2008 [13] case 2 18 months 24months (primary
adrenal insufficiency),
16.5 years (AHC with
DAX1 mutation)
↓Na,K n,
aldosterone
undectable, ↑renin,
↓cortisol
51 bp deletion
nt1068–1118
Wheeler B, 2008 [13] case 3 1 years 4 years (primary
adrenal insufficiency),
25 years (AHC with
DAX1 mutation)
↓Na,↑K, ↓cortisol
response to ACTH
test, ↑ACTH
8 bp deletion nt
1181–1188
Verrijn Stuart AA, 2007 [15] 4 weeks 4 weeks misdiagnosed
as CAH, 11 years
diagnosis of AHC
↓Na,↑K, ACTH n,
cortisol n
Mother as a carrier W105C TGG➔TGC
(missense mutation
in the amino-
terminal region
Calliari LE, 2013 [16] 8 years Na n,K n, ↓
aldosterone,
↓cortisol
2 younger brothers Transition C➔Tand
stop codon at 359
(Q359X)
Zhang Z, 2015 [17] case 1 9 years 9 years diagnosis of
primary adrenal
insufficiency, > 23 years
diagnosis of AHC
Na n,K n, ↑ ACTH,
↓cortisol
Mother as a carrier, brother
affected
c.1268delA
Zhang Z, 2015 [17] case 2 8 years 8 years diagnosis of
primary adrenal
insufficiency, 23 years
diagnosis of AHC
Na n,K n, ↑ ACTH,
↓cortisol,
↑aldosterone,
↑renin
Mother as a carrier, brother
affected
c.1268delA
Ahmad I, 2007 [18] 2.2 years ↓Na, ↑K, ↑ ACTH,
↓cortisol response
to ACTH test,
↑renin
Maternal grandmother and mother
as carriers, one maternal uncle
affected, two maternal uncles died
probably affected
T265R
Chung ST, 2015 [19] 2 weeks 4 months ↓Na, ↑K, ↑ ACTH,
↓cortisol, ↑renin,
aldosterone
undetectable
Mother as a carrier c.1094 T > C
Kyriakakis N, 2017 case 1 [20] 19 years 42 years ↓Na, K n, ↓cortisol,
↓aldosterone
c.775 T > C
Kyriakakis N, 2017 case 2 [20] 30 years 37 years ↓Na, K n, ↓cortisol
at baseline and
after ACTH test,
↓aldosterone
c.836C > T
Li N, 2017 case1 [21] 8 years 18 years ↑ ACTH, ↓cortisol,
↓aldosterone,
↑renin
Cousin affected L262P
Li N, 2017 case 2 [21] At birth 10 years ↑ ACTH, ↓cortisol,
aldosterone n,
↑renin
Cousin affected L262P
Li N, 2017 case 3 [21] 8 years 23 years ↑ ACTH, ↓cortisol,
aldosterone n,
renin
undetermined
C368F
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motifs that allow DAX-1 interacting with other proteins,
changing the normal nucleocytoplasmic ratio. Stuart et
al. described an amino-terminal DAX-1 missense muta-
tion causative of AHC associated with isolated mineralo-
corticoid deficiency [15].
The different causative mutations of DAX-1 can be re-
sponsible of the phenotypical variability, but different
clinical features between patients of the same family,
carrying the same mutations, indicate that environmen-
tal factors are involved and a detailed study of this dis-
ease also in presence of mild symptoms is essential to
make a correct diagnosis and start a prompt therapy
[16–18]. Table 2 summarizes some of the cases of DAX-
1 mutation with initial isolated hypoaldosteronism and
the main clinical and genetic characteristics described in
literature [11–13, 15–24].
Table 2 Recent cases of ACH described in literature: main clinical and genetic characteristics (Continued)
References Age at
presentation
Age at diagnosis Presentation Family history Genetic analysis
Li N, 2017 case 4 [21] At birth 27 years ↑ ACTH, Na n, K n,
cortisol n,
↓aldosterone, renin
n
637delC
Li N, 2017 case 5 [21] At birth 6 months ↑ ACTH, ↓cortisol,
↓aldosterone,
↑renin
652_653delAC
Li N, 2017 case 6 [21] 10 years 20 years ↑ ACTH, ↓cortisol,
↓aldosterone,
↑renin
973delC
Li N, 2017 case 7 [21] 2 years 15 years ACTH n, ↓cortisol,
↓aldosterone, renin
n
774_775insCC
Li N, 2017 case 8 [21] 5 years 17 years ↑ ACTH, ↓cortisol,
aldosterone and
renin
undetermined
L278P
Li N, 2017 case 9 [21] 11 years 26 years ↑ ACTH, ↓cortisol,
↓aldosterone, renin
n
Q222X
Gerster K, 2017 case 1 [22] 2.5 years 2.5 years ↓Na, ↑K, ↑ ACTH,
↓cortisol,
aldosterone and
renin
undetermined
Mother as a carrier c.870C > A
Bizzarri C, 2016 case 1 [23] 21 days ↓Na, ↑K, ↑ ACTH,
cortisol n,
aldosterone n,
↑renin
Mother as a carrier, two sisters
affected
P353LfsX387
Bizzarri C, 2016 case 2 [23] 21 days ↓Na, ↑K, ↑ ACTH,
cortisol n,
aldosterone n,
↑renin
Mother as a carrier, two sisters
affected
P353LfsX387
Bizzarri C, 2016 case 3 [23] 3 days ↓Na, K n, ↑ ACTH,
cortisol ↓,
aldosterone n,
↑renin
Mother as a carrier, two sisters
affected
P353LfsX387
Bizzarri C, 2016 case 4 [23] 8 days ↓Na, K ↑, ↑ ACTH,
cortisol ↑, ↑renin
Mother as a carrier, two sisters
affected
P353LfsX387
Al Amer AM, 2019 case 1 [24] 18 days 18months ↓Na, K ↑, ACTH n,
cortisol n,
aldosterone n,
↑renin
Case 1 and 2 are identical twins p.471 L > X
Al Amer AM, 2019 case 2 [24] 9.5 years 9.5 years ↓Na, K ↑, ACTH ↑,
cortisol ↓,
aldosterone and
renin
undetermined
Case 1 and 2 are identical twins p.471 L > X
Iughetti et al. BMC Medical Genetics           (2019) 20:98 Page 6 of 8
Replacement therapy with Hydrocortisone and Fludro-
cortisone guarantees an adequate growth of the DAX-1
patients. The only case in which growth failure was de-
tected despite optimization of therapy and nutrition was
a patient with AHC and growth hormone deficiency
(GHD) [19]. This underlines the importance of a genetic
diagnosis as soon as possible, especially in this case
where an isolated mineralocorticoid deficiency was mis-
leading the diagnosis with a treatment by fludrocortisone
only. The precocious diagnosis allowed to add hydrocor-
tisone and will improve the future management of pa-
tient’s puberty, as hypogonadotropic hypogonadism may
appear, and above all possible spermatogonia conserva-
tion before azoospermia development.
Although AHC onset is usually within the first 2
months of life, later and insidious manifestations of
symptoms may occur in childhood. Ten cases of new
adult-onset AHC have been described and diagnosis was
suspected observing the association of adrenal insuffi-
ciency and hypogonadotropic hypogonadism [20].
The onset of puberty is variable in AHC but boys usually
fail to enter puberty, gonadotropins levels are low, testoster-
one level can be normal or low and GnRH stimulation is
usually ineffective. Some patients present transient mani-
festation of secondary sex precocity, due to gonadotropin-
independent precocious puberty, ACTH-dependent preco-
cious puberty, and gonadotropin-dependent central preco-
cious puberty [25, 26]. However, usually exogenous
gonadotropins fail in stimulating a complete pubertal devel-
opment because of a primary defect in spermatogenesis. In
AHC patients, testicular biopsy demonstrates hypoplasia of
Sertoli cells and oligo-azoospermia [3, 19, 20]. DAX-1
seems to increase the Gonadotropin-releasing hormone
(GnRH) expression in the presence of SF-1 in a dose-
dependent manner, consequently decreased expression of
DAX-1 could down-regulate GnRH secretion [27]. Thus,
hormonal levels need to be monitored during the pu-
bertal period and testosterone replacement therapy
needs to be started, if puberty does not appear, to
directly stimulate virilization.
Our patient shows levels of LH and FSH within the
highest levels of normal range for 9 months of age, regu-
lar size of penis and testis, and mild high testosterone
for age. We will follow up strictly his pubertal develop-
ment, to avoid signs of precocious puberty, seen that the
minipuberty profile seems delayed or longer than usual.
Conclusion
To summarize, this case highlights that in newborn and
infant with suspicion of congenital primary hypoaldos-
teronism, glucocorticoid function should be carefully
assessed, possibly through a SST, with sometimes an in-
crease of ACTH level preceding the cortisol defect but
guiding to X-linked AHC. The phenotypical presentation
may be variable and this underlines the importance of
genetic diagnosis this leads to the correct monitoring of
the patient (puberty, sterility) and his family by identify-
ing the potential girls that are carriers.
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